
SELLAS Life Sciences Group, Inc.: updates and filings
Price
$14.86
November 19, 2026Market cap $3.0B
What Ploutos Investor adds for SELLAS Life Sciences
Part of Ploutos Investor, €9.99 a month
- The full history: 11 fiscal years, from 2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 124% since Nov 12, 2026, when the 10-Q these figures come from was filed ($8.03 then, $17.95 on Nov 18, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 11, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 17, 2026Regulation FD disclosure, other material eventsForm8-K
- Nov 12, 2026Results of operationsForm8-K
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 11, 2026Results of operationsForm8-K
- Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 31, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 27, 2026Results of operations, other material eventsForm8-K
- Jun 25, 2026Officer or director changeForm8-K
- Jun 18, 2026Shareholder voteForm8-K
- Jun 16, 2026Shares registered for employeesFormS-8
- Jun 2, 2026Other material eventsForm8-K
- May 12, 2026Results of operationsForm8-K
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 24, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
- Apr 23, 2026Annual meeting proxy statementFormDEF 14A
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 20, 2026Shelf registration for future offeringsFormS-3ASR
- Mar 19, 2026Results of operationsForm8-K
- Mar 19, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 11, 2026Other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 17, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 11, 2026 | 8-K | Results of operations | Document |
| Aug 11, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 31, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 27, 2026 | 8-K | Results of operations, other material events | Document |
| Jun 25, 2026 | 8-K | Officer or director change | Document |
| Jun 18, 2026 | 8-K | Shareholder vote | Document |
| Jun 16, 2026 | S-8 | Shares registered for employees | Document |
| Jun 2, 2026 | 8-K | Other material events | Document |
| May 12, 2026 | 8-K | Results of operations | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 24, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 23, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 23, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 20, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Mar 19, 2026 | 8-K | Results of operations | Document |
| Mar 19, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 11, 2026 | 8-K | Other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 7, 2007. Of its note and share prospectuses (424B, FWP), the newest 40 of 78.
The full analysis
What do SELLAS Life Sciences's filings show?
The filings are where every one of SELLAS Life Sciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.